Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis

NCT03606460 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03606460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03606460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2018
Completion date
May 31, 2019
Enrollment
141 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis